Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
NCT ID: NCT04527991
Last Updated: 2025-08-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
712 participants
INTERVENTIONAL
2021-01-13
2025-07-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
NCT03547973
Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...
NCT06161532
Sacituzumab Govitecan Plus EV in Metastatic UC
NCT04724018
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
NCT06524544
Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer
NCT05581589
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sacituzumab Govitecan-hziy
Participants will receive 10 mg/kg of sacituzumab govitecan-hziy intravenously on Day 1 and Day 8 of 21-day cycles.
Sacituzumab Govitecan-hziy
Administered intravenously
Treatment of Physician's Choice
Participants will have the choice of receiving paclitaxel, docetaxel, or vinflunine at standard of care (SOC) doses of 175, 75, and 320 mg/m\^2 respectively, every 3 weeks on Day 1 of 21-day cycles.
Paclitaxel
Administered intravenously
Docetaxel
Administered intravenously
Vinflunine
Administered intravenously
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sacituzumab Govitecan-hziy
Administered intravenously
Paclitaxel
Administered intravenously
Docetaxel
Administered intravenously
Vinflunine
Administered intravenously
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Tumor (T) 4b, any node (N) or
* Any T, N 2-3 Tumors of upper and lower urinary tract are permitted. Mixed histologic types are allowed if urothelial is the predominant histology.
2. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1.
3. Individuals with progression or recurrence following receipt of platinum-containing regimen and anti programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) therapy for metastatic or locally advanced unresectable disease will be enrolled.
* a. Individuals with recurrence or progression ≤12 months following completion of cisplatin-containing chemotherapy given in the neo-adjuvant/adjuvant setting may utilize that line of therapy to be eligible for the study. The 12-month period is counted from completion of surgical intervention or platinum therapy, respectively. These individuals must receive anti PD-1/PD-L1 therapy in the metastatic or locally advanced unresectable setting to be eligible.
* b. Individuals who received either carboplatin or anti PD-1/PD-L1 therapy in the neo- adjuvant/adjuvant setting will not be able to count that line of therapy towards eligibility for the study.
* c. Cisplatin ineligible individuals who meet one of the below criteria and who were treated with carboplatin in the metastatic or locally advanced unresectable settings may count that line of therapy towards eligibility. They must then have received anti PD-1/PD-L1 therapy in metastatic or locally advanced unresectable setting to be eligible for the study.
* Cisplatin ineligibility is defined as meeting one of the following criteria:
* 1\. Creatinine Clearance \< 60 mL/min
* 2\. Grade ≥ 2 Audiometric Hearing Loss
* 3\. Grade ≥ 2 Peripheral Neuropathy
* 4\. New York Heart Association (NYHA) Class III heart failure
* 5\. ECOG PS ≥ 2
* d. Anti PD-1/PD-L1 therapy administered as part of maintenance therapy may be counted towards eligibility for the study
* e. Individuals who have progressed after receiving enfortumab vedotin in prior lines of therapy, and individuals who are either ineligible or unable to tolerate enfortumab vedotin therapy, are eligible to enroll in the study
* f. Individuals who received only concurrent chemoradiation for bladder preservation without further systemic therapy are not eligible to enroll in the study. The substitution of carboplatin for cisplatin does not constitute a new regimen provided no new chemotherapeutic agents were added to the regimen and no progression was noted prior to the change in platinum.
4. Individuals with previously treated brain metastases may participate in the study provided they have stable CNS disease for at least 4 weeks prior to the first dose of study drug and stabilization of all neurologic symptoms, have no evidence of new or enlarging brain metastases, and are not using steroids \>20 mg of prednisone (or equivalent) daily for brain metastases for at least 7 days prior to first dose of the study drug.
5. Adequate hematologic counts without transfusion or growth factor support within 2 weeks of study drug initiation (hemoglobin ≥ 9 g/dL, absolute neutrophil count (ANC) ≥1,500/mm\^3, and platelets ≥100,000/µL).
6. Adequate hepatic function (bilirubin ≤1.5x institutional upper limit of normal (IULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x IULN or ≤ 5 x IULN if known liver metastases and serum albumin \>3 g/dL).
Docetaxel will only be option in TPC arm for Individuals with a total bilirubin ≤1 x IULN, and an AST and/or ALT ≤1.5x IULN if alkaline phosphatase is also \>2.5 x IULN.
7. Creatinine clearance ≥30 mL/min as assessed by the Cockcroft-Gault equation or other validated instruments (e.g. Modification of Diet in Renal Disease (MDRD) equation).
8. Females of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study drug. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
9. Females of childbearing potential must be willing to use 2 methods of birth control or be surgically sterile or abstain from heterosexual activity for the course of the study through 6 months after the last dose of study drug. Individuals of childbearing potential are those who have not been surgically sterilized or have not been free from menses for \>2 years.
10. Males must agree to use an adequate method of contraception starting with the first dose of study therapy through 6 months after the last dose of study therapy.
Exclusion Criteria
2. Have had a prior anti-cancer monoclonal antibody (mAb)/ antibody-drug conjugate (ADC) within 4 weeks prior to Cycle 1 Day 1 (C1D1) or have had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to C1D1. Individuals participating in observational studies are eligible.
3. Have received prior chemotherapy for UC with any available SOC therapies in the control arm (i.e., both prior paclitaxel and docetaxel in regions where vinflunine is not an approved therapy, or prior paclitaxel, docetaxel and vinflunine in regions where vinflunine is approved and is commercially available).
4. Have not recovered (i.e., ≤ Grade 1) from AEs due to previously administered chemotherapeutic agent.
* Note: Individuals with ≤ Grade 2 neuropathy or any grade of alopecia are an exception to this criterion and will qualify for the study.
* Note: If Individuals received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study therapy.
5. Have previously received topoisomerase 1 inhibitors.
6. Have an active second malignancy.
• Note: Individuals with a history of malignancy that have been completely treated and with no evidence of active cancer for 3 years prior to enrollment, or individuals with surgically cured tumors with low risk of recurrence are allowed to enroll in the study after discussion with the medical monitor.
7. Have active cardiac disease, defined as:
* Myocardial infarction or unstable angina pectoris within 6 months of C1D1.
* History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation), high-grade atrioventricular block, or other cardiac arrhythmias requiring anti-arrhythmic medications (except for atrial fibrillation that is well controlled with antiarrhythmic medication); history of QT interval prolongation.
* NYHA Class III or greater congestive heart failure or left ventricular ejection fraction of \<40%.
8. Have active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease) or gastrointestinal (GI) perforation within 6 months of enrollment.
9. Have an active serious infection requiring anti-infective therapy (Contact medical monitor for clarification).
10. Have known history of Human Immunodeficiency Virus (HIV)-1/2 with undetectable viral load and on medications that may interfere with SN-38 metabolism.
11. Have active Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV). In individuals with a history of HBV or HCV, individuals with a detectable viral load will be excluded.
12. Have other concurrent medical or psychiatric conditions that, in the investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations.
13. Have inability to tolerate or are allergic to any potential TPC agent or sacituzumab govitecan-hziy or unable or unwilling to receive the doses specified in the protocol.
14. Have inability to complete all specified study procedures for any reason.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gilead Sciences
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gilead Study Director
Role: STUDY_DIRECTOR
Gilead Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic - Arizona
Phoenix, Arizona, United States
UCLA Hematology/ Oncology
Los Angeles, California, United States
University of California Irvine (UCIMC)
Orange, California, United States
MedStar Washington Hospital Center
Washington D.C., District of Columbia, United States
Baptist MD Anderson Cancer Center
Jacksonville, Florida, United States
Boca Raton Clinical Research Global USA - Plantation
Plantation, Florida, United States
University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States
University of Maryland School of Medicine
Baltimore, Maryland, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Roswell Park Cancer Institute
Buffalo, New York, United States
Weill Cornell Medical College
New York, New York, United States
Montefiore Medical Center
The Bronx, New York, United States
Cleveland Clinic
Cleveland, Ohio, United States
Oklahoma Cancer Specialists and Research Institute (OCSRI)
Tulsa, Oklahoma, United States
Penn State Hershey Cancer Institute
Hershey, Pennsylvania, United States
Thompson Oncology Group - Knoxville Downtown
Knoxville, Tennessee, United States
University Cancer Specialists - Knoxville
Knoxville, Tennessee, United States
Harold C. Simmons Comprehensive Cancer Center
Dallas, Texas, United States
Center for Cancer and Blood Disorders
Fort Worth, Texas, United States
Seattle Cancer Care Alliance (SCCA)
Seattle, Washington, United States
Summit Cancer Centers
Spokane, Washington, United States
Chris O'Brien Lifehouse
North Ryde, New South Wales, Australia
Calvary Mater Newcastle
Waratah, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Icon Cancer Centre Wesley
Auchenflower, Queensland, Australia
Southern Adelaide Local Health Network Incorporated
Bedford Park, South Australia, Australia
Ashford Cancer Centre Research - ICON Cancer Centre Adelaide
Kurralta Park, South Australia, Australia
ICON Cancer Centre Hobart
Hobart, Tasmania, Australia
Monash Health
Clayton, Victoria, Australia
Austin Health
Heidelberg, Victoria, Australia
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
Sunshine Hospital
Saint Albans, Victoria, Australia
Liverpool Hospital
Nedlands, Western Australia, Australia
Sir Charles Gairdner Hospital
Nedlands, Western Australia, Australia
Universitätsklinik für Innere Medizin Graz
Graz, , Austria
Ordensklinikum Linz GmbH Barmherzige Schwestern
Linz, , Austria
Krankenhaus Der Barmherzigen Bruder Wien
Vienna, , Austria
Grand Hôpital De Charleroi - Notre Dame
Charleroi, , Belgium
Az Maria Middelares Ghent
Ghent, , Belgium
Universitair Ziekenhuis Gent
Ghent, , Belgium
Universitair Ziekenhuis Leuven
Leuven, , Belgium
Centre Hospitalier Universitaire de Liège
Liège, , Belgium
Multiprofile Hospital for Active Treatment Heart and Brain EAD
Pleven, , Bulgaria
Specialized Hospital for Active Treatment of Oncological Diseases - Sofia District
Sofia, , Bulgaria
Cross Cancer Institute
Edmonton, , Canada
qeii health sciences centre - VG site
Halifax, , Canada
Juravinski Hospital and Cancer Centre
Hamilton, , Canada
London Health Sciences Centre
London, , Canada
Jewish General Hospital
Montreal, , Canada
McGill University Health Centre
Montreal, , Canada
R.S. McLaughlin Durham Regional Cancer Centre
Oshawa, , Canada
Princess Margaret Cancer Centre
Toronto, , Canada
British Columbia Cancer Agency-Vancouver Centre
Vancouver, , Canada
Peking University First Hospital
Beijing, , China
Chinese People's Liberation Army General Hospital - 301 Hospital
Beijing, , China
Beijing Cancer Hospital
Beijing, , China
Chinese Academy of Medical Sciences Cancer Hospital
Beijing, , China
1st Hospital Jilin University
Changchun, , China
Hunan Cancer Hospital - Xiangya Hospital - Central South University
Changsha, , China
West China Hospital Sichuan University
Chengdu, , China
Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital
Chengdu, , China
Chongqing University Cancer Hospital
Chongqing, , China
The First Affiliated Hospital of Fujian Medical University
Fujian, , China
Union Hospital of Fujian Medical University
Fuzhou, , China
Sun Yat-Sen University Cancer Center
Guangzhou, , China
Zhejiang Provincial People's Hospital - Zhaohui
Hangzhou, , China
Cancer Hospital of the University of Chinese Academy of Sciences Zhejiang Cancer Hospital
Hangzhou, , China
Anhui Provincial Cancer Hospital
Hefei, , China
Qilu Hospital of Shandong University
Jinan, , China
The First Affiliated Hospital of Nanchang University
Nanchang, , China
Nanjing Drum Tower Hospital
Nanjing, , China
Liaoning Cancer Hospital and Institute
Shenyang, , China
Tianjin Medical University Cancer Institute & Hospital
Tianjin, , China
Affiliated Tumor Hospital of Xinjiang Medical University
Ürümqi, , China
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, , China
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, , China
Clinical Hospital Centre Split
Split, , Croatia
Clinical Hospital Centre "Sestre Milosrdnice"
Zagreb, , Croatia
University Hospital Centre Zagreb
Zagreb, , Croatia
Fakultni nemocnice Olomouc
Olomouc, , Czechia
Urocentrum Praha
Prague, , Czechia
Ramsay Health Clinic Belharra
Bayonne, , France
CHU Saint Andre
Bordeaux, , France
Centre Hospiltalier Universitaire Brest - Hôpital Morvan
Brest, , France
Centre Francois Baclesse
Caen, , France
Centre Jean Perrin
Clermont-Ferrand, , France
Centre Georges- Francois Leclerc
Dijon, , France
Centre Hospitalier Departemental Vendee
La Roche-sur-Yon, , France
Centre Oscar Lambret
Lille, , France
Centre Leon Berard
Lyon, , France
Institut Régional du Cancer de Montpellier ICM Val d' Aurelle
Montpellier, , France
Centre Antoine Lacassagne
Nice, , France
Centre Hospitalier Universitaire de Nimes
Nîmes, , France
Hôpital Européen Georges-Pompidou
Paris, , France
Centre Eugene Marquis
Rennes, , France
Centre Hospitalier Privé Saint-Grégoire
Saint-Grégoire, , France
Les Hôpitaux Universitaires de Strasbourg
Strasbourg, , France
Hôpital Foch
Suresnes, , France
Institut Claudius Regaud
Toulouse, , France
Institut Gustave Roussy
Villejuif, , France
High Technology Hospital MedCenter
Batumi, , Georgia
New Hospitals
Tbilisi, , Georgia
L. Managadze National Center of Urology
Tbilisi, , Georgia
Evex Medical corporation
Tbilisi, , Georgia
Jerarsi Clinic
Tbilisi, , Georgia
Universitatsklinik Dresden
Dresden, , Germany
Malteser Waldkrankenhaus Erlangen
Erlangen, , Germany
Universitätsklinikum Essen
Essen, , Germany
Centrum fur Hamatologie und Onkologie Bethanien
Frankfurt am Main, , Germany
Asklepios Klinik Altona
Hamburg, , Germany
Institut Für Versorgungsforschung in Der Onkologie
Koblenz, , Germany
Universitatsklinikum Munster
Münster, , Germany
Studienpraxis Urologie
Nürtingen, , Germany
Universitätsklinikum Tübingen
Tübingen, , Germany
Charité Universitätsmedizin Berlin - Campus Benjamin Franklin
Wien, , Germany
401 General Military Hospital of Athens
Athens, , Greece
Henry Dunant Hospital
Athens, , Greece
Alexandra General Hospital
Athens, , Greece
Attikon Hospital
Chaïdári, , Greece
Regional University General Hospital of Herakleio, Crete
Herakleio, , Greece
University Hospital Of Ioannina
Ioannina, , Greece
University Hospital of Larissa
Larissa, , Greece
Athens Medical Center
Marousi, , Greece
University Hospital of Patras
Pátrai, , Greece
Bioclinic - Thessaloniki
Thessaloniki, , Greece
Theagenio Anticancer Hospital of Thessaloniki
Thessaloniki, , Greece
Anassa General Clinic
Thessaloniki, , Greece
Interbalkan Medical Center of Thessaloniki
Thessaloniki, , Greece
Prince of Wales Hospital
Hong Kong, , Hong Kong
Queen Mary Hospital
Hong Kong, , Hong Kong
Hong Kong United Oncology Centre
Kowloon, , Hong Kong
Tallaght University Hospital
Dublin, , Ireland
University Hospital Waterford
Waterford, , Ireland
Shamir Medical Center (Assaf Harofeh)
Be’er Ya‘aqov, , Israel
Rambam Health Care Campus
Haifa, , Israel
Hadassah University Hospital Ein Kerem
Jerusalem, , Israel
Meir Medical Center
Kfar Saba, , Israel
Rabin Medical Center
Petah Tikva, , Israel
Tel Aviv Medical Center (Ichilov Hospital)
Tel Aviv, , Israel
Chaim Sheba Medical Center
Tel Litwinsky, , Israel
Ospedale San Donato
Arezzo, , Italy
Centro di Riferimento Oncologico di Aviano
Aviano, , Italy
Istituto Tumori Bari Giovanni Paolo II - IRCCS
Bari, , Italy
Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia
Candiolo (TO), , Italy
Ospedale Policlinico San Martino
Genova, , Italy
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
Meldola, , Italy
Ospedale San Raffaele
Milan, , Italy
Azienda Ospedaliero Universitaria Maggiore Della Carita
Novara, , Italy
Azienda Ospedaliero Universitaria Pisana
Pisa, , Italy
Istituto Regina Elena
Roma, , Italy
Università Campus Bio-Medico di Roma
Rome, , Italy
Ospedale Civile Di Sondrio
Sondrio, , Italy
Azienda Ospedaliera Santa Maria di Terni
Terni, , Italy
Azienda Ospedaliero-Universitaria San Luigi Gonzaga
Torino, , Italy
Ospedale di Trento - Presidio Ospedaliero Santa Chiara
Trento, , Italy
Azienda Ospedaliera Universitaria Integrata Verona
Verona, , Italy
Hospital de Braga
Braga, , Portugal
Unidade Local de Saúde da Guarda - Hospital Sousa Martins
Guarda, , Portugal
Centro Hospitalar de Leiria - Hospital de Santo André
Leiria, , Portugal
Centro Hospitalar de Lisboa Norte - Hospital de Santa Maria
Lisbon, , Portugal
Instituto Portugues de Oncologia do Porto Francisco Gentil, E.P.E
Porto, , Portugal
Centro Hospitalar de Tras-os-Montes e Alto Douro
Vila Real, , Portugal
BRCR Medical Center, Inc
San Juan, PR, Puerto Rico
National University Hospital
Singapore, , Singapore
Icon Cancer Centre Farrer Park
Singapore, , Singapore
Tan Tock Seng Hospital
Singapore, , Singapore
Pusan National University Hospital
Busan, , South Korea
Chungbuk National University Hospital
Cheongju-si, , South Korea
Chungnam National University Hospital
Daejeon, , South Korea
National Cancer Center
Goyang-si, , South Korea
Pusan National University Yangsan Hospital
Gyeongsangnam-do, , South Korea
Gachon University Gil Medical Center
Incheon, , South Korea
Seoul National University Bundang Hospital
Seongnam-si, , South Korea
Seoul National University Hospital
Seoul, , South Korea
Severance Hospital, Yonsei University Health System
Seoul, , South Korea
Asan Medical Center
Seoul, , South Korea
Samsung Medical Center
Seoul, , South Korea
The Catholic University of Korea Seoul Saint Mary's Hospital
Seoul, , South Korea
The Catholic University of Korea Saint Vincent's Hospital
Suwon, , South Korea
Hospital del Mar - Parc de Salut
Barcelona, , Spain
Hospital Universitari Vall D'Hebron
Barcelona, , Spain
Hospital Clinic de Barcelona
Barcelona, , Spain
Hospital Reina Sofia
Córdoba, , Spain
Hospital General Universitario Gregorio Maranon
Madrid, , Spain
Clínica Universidad de Navarra - Madrid
Madrid, , Spain
MD Anderson Cancer Center
Madrid, , Spain
Hospital Universitario Ramon y Cajal
Madrid, , Spain
Hospital Universitario 12 de Octubre
Madrid, , Spain
Hospital Universitario Puerta de Hierro de Majadahonda
Majadahonda, , Spain
Hospital Sant Joan de Déu de Manresa
Manresa, , Spain
Complexo Hospitalario de Ourense (CHOU)
Ourense, , Spain
Clinica Universidad de Navarra
Pamplona, , Spain
Hospital Universitario Marqués de Valdecilla
Santander, , Spain
Hospital Universitario Virgen del Rocio
Seville, , Spain
Álvaro Cunqueiro Hospital
Vigo, , Spain
Länssjukhuset Ryhov
Jönköping, , Sweden
Universitetssjukhuset i Linköping
Linköping, , Sweden
Karolinska Universitetssjukhuset - Solna
Stockholm, , Sweden
University Hospital Basel
Basel, , Switzerland
Istituto Oncologico Della Svizzera Italiana (IOSI)
Bellinzona, , Switzerland
University of Bern
Bern, , Switzerland
Hôpitaux Universitaires de Genève
Geneva, , Switzerland
Universitaetsspital Zurich - Klinik fur Medizinische Onkologie und Hematologie
Zurich, , Switzerland
Chiayi Chang Gung Memorial Hospital
Buzi, , Taiwan
Kaohsiung Veterans General Hospital
Kaohsiung City, , Taiwan
Kaohsiung Chang Gung Memorial Hospital
Kaohsiung City, , Taiwan
Taipei Tzu Chi General Hospital
New Taipei City, , Taiwan
China Medical University Hospital
Taichung, , Taiwan
Taichung Veterans General Hospital
Taichung, , Taiwan
National Cheng Kung University Hospital
Tainan City, , Taiwan
National Taiwan University Hospital
Taipei, , Taiwan
Taipei Veterans General Hospital
Taipei, , Taiwan
Chang Gung Memorial Hospital - Linkou Branch
Taoyuan District, , Taiwan
Hacettepe Universitesi Tip Fakultesi- Kanser Enstitusu
Ankara, , Turkey (Türkiye)
Trakya Universitesi Saglik Arastirma ve Uygulama Merkezi
Edirne, , Turkey (Türkiye)
Bagcilar Medipol Mega Universite Hastanesi
Istanbul, , Turkey (Türkiye)
Istanbul Acibadem University Maslak Hospital
Istanbul, , Turkey (Türkiye)
T.C. Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi
Istanbul, , Turkey (Türkiye)
Medical Park Izmır Hastanesi
Izmir, , Turkey (Türkiye)
Cebeci Hastanesi
Mamak, , Turkey (Türkiye)
VKV Amerikan Hastanesi Department of Oncology
Şişli, , Turkey (Türkiye)
University Hospitals Birmingham NHS Foundation Trust
Birmingham, , United Kingdom
Dorset County Hospital NHS Foundation Trust
Dorchester, , United Kingdom
NHS Greater Glasgow and Clyde
Glasgow, , United Kingdom
Barts Health NHS Trust
London, , United Kingdom
Guys and Saint Thomas NHS Foundation Trust, Guy's Hospital
London, , United Kingdom
Sarah Cannon Research Institute London
London, , United Kingdom
The Christie NHS Foundation Trust
Manchester, , United Kingdom
East and North Hertfordshire NHS Trust
Middlesex, , United Kingdom
Oxford University Hospitals NHS Foundation Trust
Oxford, , United Kingdom
Swansea Bay University Health Board
Port Talbot, , United Kingdom
Royal Preston Hospital
Preston, , United Kingdom
The Royal Marsden NHS Foundation Trust
Surrey, , United Kingdom
The Royal Wolverhampton NHS Trust
Wolverhampton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Powles T, Tagawa S, Vulsteke C, Gross-Goupil M, Park SH, Necchi A, De Santis M, Duran I, Morales-Barrera R, Guo J, Sternberg CN, Bellmunt J, Goebell PJ, Kovalenko M, Boateng F, Sierecki M, Wang L, Sima CS, Waldes J, Loriot Y, Grivas P. Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial. Ann Oncol. 2025 May;36(5):561-571. doi: 10.1016/j.annonc.2025.01.011. Epub 2025 Feb 11.
Related Links
Access external resources that provide additional context or updates about the study.
Gilead Clinical Trials Website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-513870-23
Identifier Type: OTHER
Identifier Source: secondary_id
IMMU-132-13
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.